Skip to main content

Research Repository

Advanced Search

Duramycin-induced calcium release in cancer cells

Broughton, Laura J.; Crow, Chris; Madden, Leigh A.; Maraveyas, Anthony


Chris Crow


Introduction: Duramycin through binding with phosphatidylethanolamine (PE) has shown potential to be an effective anti-tumour agent. However its mode of action in relation to tumour cells is not fully understood. Methods: PE expression on the surface of a panel of cancer cell lines was analysed using duramycin and subsequent antibody labelling then analysed by flow cytometry. Cell viability was also assessed via flow cytometry using annexin V and propidium iodide (PI). Calcium ion (Ca²⁺) release by tumour cells in response to duramycin was determined by spectrofluorometry following incubation with Fluo-3, AM. Confocal microscopy was performed on the cancer cell line AsPC-1 to assess real time cell response to duramycin treatment. Results: Duramycin was able to detect cell surface PE expression on all 15 cancer cell lines screened, which was shown to be duramycin concentration dependent. However higher concentrations induced necrotic cell death. Duramycin induced calcium ion (Ca²⁺) release from the cancer cell lines also in a concentration and time dependent manner. Confocal microscopy showed an influx of PI into the cells over time and induced morphological changes. Conclusion: Duramycin induces Ca²⁺ release from cancer cell lines in a time and concentration dependent relationship.


Broughton, L. J., Crow, C., Madden, L. A., & Maraveyas, A. (2016). Duramycin-induced calcium release in cancer cells. Anti-cancer drugs, 27(3), 173-182.

Journal Article Type Article
Acceptance Date Oct 3, 2015
Publication Date 2016-03
Deposit Date Dec 2, 2015
Publicly Available Date Nov 23, 2017
Journal Anti-cancer drugs
Print ISSN 0959-4973
Electronic ISSN 1473-5741
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 27
Issue 3
Pages 173-182
Keywords Duramycin, Phosphatidylethanolamine, Calcium release
Public URL
Publisher URL
Additional Information This is a non-final version of an article published in final form in Anti-Cancer Drugs. 27(3):173-182, March 2016.